The venture capital company Inveready has acquired Enantia, a company specialized in contract research (CRO). Both companies are members of CATALONIA.HEALTH. The acquisition has been done through INVACO, one of the companies controlled by the venture capital fund Inveready Biotech IV. This strategic acquisition marks the beginning of an ambitious growth plan, which includes the integration of small specialized CROs to provide comprehensive R&D services.
The operation has the participation of the Enantia management team as shareholders, reinforcing its commitment to the future of the company. The collaboration between Enantia and Inveready will facilitate the expansion to new markets while executing a specific acquisition strategy to consolidate a highly specialized CRO group that serves the pharmaceutical, biotechnological and materials industries.
Joan Feixas, CEO of Enantia, commented: "We are grateful for Inveready’s trust in Enantia and our management team to lead the creation of a specialized R&D services group. This partnership comes at the right moment and under the right circumstances to drive significant growth. We are excited to be part of this project and look forward to expanding our impact in life sciences and beyond.”
Sara Secall, partner of Inveready, stated: “The preclinical CRO sector in Spain is highly fragmented. We created INVACO with the goal of acquiring specialized CROs in life sciences, and Enantia is the first step in building a stronger and more integrated group. This acquisition provides an exit for historical shareholders while ensuring the commitment of Enantia’s management team, who now hold a stake in INVACO. Our plan is to integrate additional CROs focused on preclinical drug development, including formulations, analytical and bioanalytical methods, toxicology, and pilot production.”
Comments